Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
Open Access
- 30 December 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 645
Abstract
CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in multiple myeloma (MM), making them ideal therapeutic targets. Anti-CD38 monoclonal antibodies, such as approved daratumumab and isatuximab, are currently the milestone in MM treatment because they induce plasma cell apoptosis and kill through several mechanisms, including antibody-dependent cellular cytotoxicity or phagocytosis. BCMA is considered an excellent target in MM, and three different therapeutic strategies are either already available in clinical practice or under investigation: antibody–drug conjugates, such as belantamab-mafodotin; bispecific T cell engagers; and chimeric antigen receptor-modified T cell therapies. Despite the impressive clinical efficacy of these new strategies in the treatment of newly diagnosed or multi-refractory MM patients, several mechanisms of resistance have already been described, including antigen downregulation, the impairment of antibody-dependent cell cytotoxicity and phagocytosis, T- and natural killer cell senescence, and exhaustion. In this review, we summarize the current knowledge on the mechanisms of action and resistance of anti-CD38 and anti-BCMA agents and their clinical efficacy and safety.Keywords
This publication has 169 references indexed in Scilit:
- Killer Ig–like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantationBlood, 2011
- Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibitionBlood, 2010
- Plasma cell development and survivalImmunological Reviews, 2010
- 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma CellsClinical Cancer Research, 2009
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and PathologyPhysiological Reviews, 2008
- Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myelomaBritish Journal of Haematology, 2007
- Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cellsBlood, 2005
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005
- Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalBlood, 2004
- What is trogocytosis and what is its purpose?Nature Immunology, 2003